CLOs on the Move

Dimension Therapeutics

www.dimensiontx.com

 
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

MedAxiom

MedAxiom is a Neptune Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kyros

Kyros is committed to breaking down barriers, creating a community of support, and making a lasting impact on the lives of those affected by SUD. Through innovative training models, compassionate peer support, and a focus on human-centered solutions, Kyros strives to redefine recovery and provide hope for a healthier future. Founded in 2021 by Daniel Larson, after he encountered obstacles in his own journey with substance use disorder, Kyros` mission is to increase positive outcomes for the millions of Americans managing their own recovery or dedicating their lives to help others find support and wellbeing.

Caris Diagnostics

Caris Diagnostics is a Irving, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

GTESS Corporation

GTESS Corporation is a Richardson, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Berg LLC

BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.